The Cardio Diabetology Era. A Concise and Illustrated Review: Four Phenotypes and Three New Evidence-Based and Practical Therapeutic Algorithms

Main Article Content

Enrique C. Morales-Villegas

Abstract

Type 2 diabetes mellitus (T2DM) has undergone therapeutic approaches evolving from glucocentricity towards holism, in which it is currently considered a microvascular and macrovascular risk condition determined by multiple variables beyond glucose. These include visceral adiposity, metaflammation, insulin resistance with its hemodynamic (endothelial dysfunction and hypertension) and metabolic (mixed dyslipidemia) surrogates; together with other metabolic regulation system dysfunction such as the incretin system, sodium, and glucose cotransporters at the intestinal and renal level, and the intestinal microbiota, among the most studied.


Therefore, the current treatment of this risk condition called T2DM, includes the control of all its determining factors: adiposity through a healthy diet, aerobic physical activity, and/or drugs such as glucagon-like peptide-1 receptor agonists (GLP1-RA) or bariatric surgical procedures. Inflammation remains a therapeutic target under investigation, although it has not yet been transferred to clinical practice guidelines. Insulin resistance and its hemodynamic and metabolic subrogates are the therapeutic targets of multiple pharmacological interventions, essentially insulin sensitizers, inhibitors of the renin-angiotensin-aldosterone system, facilitators of the transformation and elimination of lipoproteins with apo-B100 as omega-3 ultra-purified fatty acids, fibrates, antisense oligonucleotides (ASO) against apoC3, ASO and monoclonal antibodies (mAbs) anti-ANGPTL3, statins, ezetimibe, mAbs and small interfering RNA (siRNA) anti-PCSK9, among others.


In the last 14 years, drugs such as the dipeptidyl peptidase 4 (DPP-4) inhibitors, GLP1-RA, and, more recently, the dual GIP-GLP-1 analogs, have been incorporated to correct the dysfunction of the incretin system, as well as many others that inhibit the intestinal and renal reabsorption of sodium and glucose as sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitors. Surprisingly, new drugs have emerged between the GLP1-RA and the SGLT2/1 inhibitors that, beyond their essential therapeutic effect (glucose control), have shown brain, cardiac, and renal protection of variable magnitude. Finally, manipulating the intestinal microbiota is a strategy under extensive investigation and incipient clinical application.


From this summary, it is clear that the current therapeutic landscape in T2DM has expanded dramatically, from a “gluco-panorama” focused on glucose control with insulin, sulfonylureas, metformin, and glitazones, to a “holo-panorama” incorporating five new therapeutic classes and at least eighteen new "anti-diabetic" drugs, in addition to a similar number of medications for hypertension and dyslipidemia control.

Article Details

How to Cite
MORALES-VILLEGAS, Enrique C.. The Cardio Diabetology Era. A Concise and Illustrated Review: Four Phenotypes and Three New Evidence-Based and Practical Therapeutic Algorithms. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3207>. Date accessed: 06 dec. 2022. doi: https://doi.org/10.18103/mra.v10i10.3207.
Section
Review Articles

References

1. Alegre-Díaz J, Herrington W, López-Cervantes M et al. Diabetes and Cause-Specific Mortality in Mexico City. N Engl J Med. 2016; 375:1961-1971.
2. Gaede P, Vedel P, Parving HH et al. Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus and Microalbuminuria: The Steno Type 2 Randomized Study. Lancet. 1999; 353:61722.
3. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med. 2008; 358:580-591.
4. Gaede P, Vedel P, N Larsen et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med. 2003; 348:383-393.
5. Rawshani A, Rawshani A, Franzén S et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017; 376:1407-1418.
6. Rawshani A, Rawshani A, Franzén S et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018; 379:633-644.
7. Davies MJ, D´ Alessio D, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. DOI: 10-1007/s00125-018-4729-5.
8. Cosentino F, Grant PJ et al. 2019 ESC Guidelines on Diabetes, Prediabetes and Cardiovascular Disease developed in Collaboration with EASD. Eur Heart J. 2019; 00:01-69.
9. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Supplement_1) S1–S2. Doi: 10.2337/dc22-Sint.
10. Scirica BM, Bhatt DI, Braunwald E et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013; 369:1317-1326. DOI: 10.1056/NEJMoa1307684.
11. White WB, Cannon CP, Heller SR et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013; 369:1327-1335. DOI: 10.1056/NEJMoa1305889.
12. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373:232-242. DOI : 10.1056/NEJMoa1501352.
13. Rosenstock J, Perkovik V, Johansen OE et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk. The CARMELINA Randomized Clinical Trial. JAMA. 2019; 321:69-79. DOI: 10.1001/jama.2018.18269.
14. Rosenstock J, Kahn SE, Johansen OE et al. Effect of Linagliptin vs Glimepiride on Major Cardiovascular Outcomes in Adults with Type 2 Diabetes. The CAROLINA Randomized Clinical Trial. JAMA. 2019; 322:1155-1166. DOI:10.1001/jama.2019.13772.
15. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373:2247-2257. DOI: 10.1056/NEJMoa.1509225.
16. Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375:1834-1844. DOI: 10.1056/NEJMoa1607141.
17. Husain M, Birkenfeld AL, Donsmark M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019; 381:841-851. DOI: 10.1056/NEJMoa1901118.
18. Holman RR, Bethel MA, Mentz RJ et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377:1228-1239. DOI: 10.1056/NEJMoa1612917.
19. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Lancet. 2018; 392:1519-1529. DOI: 10.1016/S0140-6736(18)32261X.
20. Gerstein HC, Colhoun HM, Degenais DR et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): a double-blind, placebo-controlled trial. Lancet. 2019. 394:121-130. DOI: 10.1016/S0140-6736(19)31149-3.
21. Gerstein HC, Sattar N, Rosenstock J et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med, 2020. New Engl J Med. 2021; 385:896-907. DOI: 10.1056/NEJMoa2108269
22. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373:2117-2128. DOI: 10.1056/NEJMoa1504720.
23. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383:1413-1424. DOI: 10.1056/NEJMoa2022190.
24. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2021; 385:1451-1461. DOI: 10.1056/NEJMoa2107038.
25. The Study of Heart and Kidney Protection with Empagliflozin (EMPA-Kidney). NCT Identifier: 03594110. https://clinicaltrials.gov.
26. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377:644-657. DOI: 10.1056/NEJMoa1611925.
27. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380:2295-2396. DOI: 10.1056/NEJMoa1811744.
28. Wiviott SD, Bonaca MP, Mosenzon O et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019; 380:347-357. DOI: 10.1056/NEJMoa1812389.
29. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381:1995-2008. DOI: 10.1056/NEJMoa1911303.
30. Heerspink HJL, Stefansson VB, Correa-Rotter R et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383:1436-1446. DOI: 10.1056/NEJMoa2024816.
31. Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; published online August 27, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2206286
32. Cannon CP, Pratley R, Dagogo-Jack S et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020; 383:1425-1435. DOI: 10.1056/NEJMoa2004967.
33. Bhatt DL, Szarek M, Steg PG et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2020; 384:117-128. DOI: 10.1056/NEJMoa2030183
34. Bhatt DL, Szarek M, Pitt B et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021; 384:129-139. DOI: 10.1056/NEJMoa2030186.
35. Marso SP, McGuire DK, Zinman B et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017; 377:723-732. DOI 10.1056/NEJMoa1615692.
36. Morales-Villegas E. Cardio Diabetología. Third Edición 2022. Control Integral de la Diabetes Mellitus tipo 2 con enfoque cerebro, cardio, renal. Editorial Atheros CIC. ISBN 978-607-29-3325-5
37. Mozenson O, Alguwaihes A, Arenas-Leon JL et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease Prevalence in Adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021; 29:154. DOI: 10.1186/S12933-021-01344-0.
38. Lloyd-Jones DM, Braun LT, Ndumele CE et al, Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease, Journal of the American College of Cardiology (2018). DOI: 10.1016/j.jacc.2018.11.005.
39. Mach F, Baigent C, Catapano A et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal (2019) 00, 1-78. DOI: 10.1093/eurheartj/ehz455
40. he GRADE Study Research Group. Glycemia Reduction in Type 2 Diabetes. Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022; 387:1075-1085. DOI: 10.1056/NEJMoa2200436.